Navarro-Alarcón Miguel, Gil-Hernández Fernando, Sánchez-González Cristina, Llopis Juan, Villalón-Mir Marina, Olmedo Pablo, Alarcón-Guijo Pablo, Salagre Diego, Gaona Lorena, Paredes Mario, Agil Ahmad
Department of Nutrition and Bromatology, School of Pharmacy, University of Granada, 18016 Granada, Spain.
Department of Toxicology, School of Medicine, University of Granada, 18071 Granada, Spain.
Pharmaceutics. 2021 Sep 22;13(10):1535. doi: 10.3390/pharmaceutics13101535.
Melatonin improves metabolic alterations associated with obesity and its diabetes (diabesity). We intend to determine whether this improvement is exerted by changing Zn and/or Cu tissue levels in liver, muscle, pancreas, and brain, and in internal (perirenal, perigonadal, and omentum) and subcutaneous lumbar white adipose tissues (IWAT and SWAT, respectively). Male Zücker diabetic fatty (ZDF) rats and lean littermates (ZL) were orally supplemented either with melatonin (10 mg/kg body weight/day) or vehicle for 6 weeks. Zn and Cu concentrations were not significantly influenced by diabesity in the analyzed tissues ( > 0.05), with the exception of Zn in liver. In skeletal muscle Zn and Cu, and in perirenal WAT, only Zn levels increased significantly with melatonin supplementation in ZDF rats ( < 0.05). This cytoplasmic Zn enhancement would be probably associated with the upregulation of several Zn influx membrane transporters (Zips) and could explain the amelioration in the glycaemia and insulinaemia by upregulating the Akt and downregulating the inhibitor PTP1B, in obese and diabetic conditions. Enhanced Zn and Cu levels in muscle cells could be related to the reported antioxidant melatonin activity exerted by increasing the Zn, Cu-SOD, and extracellular Cu-SOD activity. In conclusion, melatonin, by increasing the muscle levels of Zn and Cu, joined with our previously reported findings improves glycaemia, insulinaemia, and oxidative stress in this diabesity animal model.
褪黑素可改善与肥胖及其糖尿病(糖尿病性肥胖症)相关的代谢改变。我们旨在确定这种改善是否是通过改变肝脏、肌肉、胰腺、大脑以及内脏(肾周、性腺周围和网膜)和皮下腰部白色脂肪组织(分别为内脏白色脂肪组织和皮下白色脂肪组织)中的锌和/或铜组织水平来实现的。雄性 Zucker 糖尿病脂肪大鼠(ZDF)和瘦的同窝仔鼠(ZL)分别口服补充褪黑素(10 毫克/千克体重/天)或赋形剂,持续 6 周。除肝脏中的锌外,分析组织中的锌和铜浓度不受糖尿病性肥胖症的显著影响(P>0.05)。在骨骼肌中的锌和铜以及肾周白色脂肪组织中,只有 ZDF 大鼠补充褪黑素后锌水平显著升高(P<0.05)。这种细胞质锌的增加可能与几种锌流入膜转运蛋白(Zips)的上调有关,并且可以解释在肥胖和糖尿病条件下通过上调 Akt 和下调抑制剂 PTP1B 来改善血糖和胰岛素血症。肌肉细胞中锌和铜水平的升高可能与通过增加锌、铜超氧化物歧化酶(Cu-SOD)和细胞外 Cu-SOD 活性所报道的褪黑素抗氧化活性有关。总之,褪黑素通过增加肌肉中的锌和铜水平,结合我们先前报道的结果,改善了这种糖尿病性肥胖动物模型中的血糖、胰岛素血症和氧化应激。